Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-08-01

Clinical Trial Update: A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 study of vemurafenib in metastatic melanoma, including patients with brain metastases, has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2016-08-01